Challenges and Acquisitions: Pfizer's Struggle with Patent Expiration and Weak Pipeline

Explore Pfizer's struggle with drug patent expirations and their plans to use Covid-related sales to address their weak new drug pipeline. The chapter also mentions the company's recent acquisitions and compares its performance to Eli Lilly.